Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects
Year: 2020
Type: article
Study design: Observational Study
Abstract: COPD, chronic bronchitis (CB) and active smoking have all been associated with goblet cell hyperplasia (GCH) in small studies. Active smoking is strongly associated with CB, but there is a disconnect between CB clinical symptoms and pathology. Chronic cough and sputum production poorly correlate with the presence of GCH or COPD. We hypothesized that the primary determinant of GCH in ever smokers with or without airflow obstruction is active smoking. Goblet Cell Density (GCD) was measured in 71 current or former smokers [32 subjects without COPD and 39 COPD subjects]. Endobronchial mucosal biopsies were stained with Periodic Acid Schiff-Alcian Blue, and GCD was measured as number of goblet cells/mm basement membrane. GCD was divided into tertiles based on log10 transformed values. Log10GCD was greater in current smokers compared to former smokers. Those with classically defined CB or SGRQ defined CB had a greater log10 GCD compared to those without CB. Current smoking was independently associated with tertile 3 (high log10GCD) whereas CB was not in multivariable regression when adjusting for lung function and demographics. These results suggest that GCH is induced by active smoke exposure and does not necessarily correlate with the clinical symptoms of CB.
Source: Scientific Reports
Authors: Victor Kim, Stephanie Jeong, Huaqing Zhao, Mehmet Kesimer, Richard C. Boucher, J. Michael Wells, Stephanie A. Christenson, MeiLan K. Han, Mark Dransfield, Robert Paine, Christopher B. Cooper, Igor Barjaktarevic, Russell Bowler, Jeffrey L. Curtis, Robert J. Kaner, Sarah L. O’Beirne, Wanda K. O’Neal, Stephen I. Rennard, Fernando J. Martinez, Prescott G. Woodruff
Institutions: Temple University, University of North Carolina at Chapel Hill, University of Alabama at Birmingham, University of California, San Francisco, University of Michigan, University of Utah, University of California, Los Angeles, National Jewish Health, Michigan Medicine, Weill Cornell Medicine, University of Nebraska Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,870
Funders: Foundation for the National Institutes of Health, AstraZeneca, GlaxoSmithKline, Sanofi, Ikaria, Chiesi Farmaceutici, COPD Foundation, Novartis Pharmaceuticals Corporation, Sunovion, Regeneron Pharmaceuticals, Mylan, Forest Research Institute, Grifols, National Institutes of Health, National Heart, Lung, and Blood Institute
Awards: G1488133927, G1672953414, G2099663897, G2126848096, G2212190077, G2847413391, G3027037974, G3868091120, G3999916299, G4039356828, G409135471, G4578545918, G4586241626, G4671684786, G4749522346, G4940690932, G4975107759, G5195001291, Identifying the Th2 endotype in COPD: clinical and pathologic implications, G5434367891, G5510456481, G5566143793, G5878489336, G6107646161, G6112557991, G67127270, G7206313631, G87279447, G8837091488, G8957911378, G9000169132, G9000184499, Mentoring Research in Precision Medicine for Lung Disease
OpenAlex ID: W3104780801